Figure 3

Transient hematological changes with 12 μg dose of rHuIL-12 or placebo in phase 1b expansion study. Standard hematologic methods were used to determine cell counts at the indicated time points. The mean percentage of baseline count after treatment with rHuIL-12 (12 μg) or placebo are shown as follows: A) lymphocytes, neutrophils, platelets, and reticulocytes after treatment with rHuIL-12; B) lymphocytes, neutrophils, platelets, and reticulocytes after treatment with placebo; C) CD45+, CD3+, CD4+ and CD8+ cells after rHuIL-12; D) CD45+, CD3+, CD4+ and CD8+ cells after rHuIL-12; D) NK and CD34+ after placebo; E) NK and CD34+ cells after rHuIL-12; F) NK and CD34+ cells after placebo. NK cells were defined as CD45 + CD16 + CD56+ triple positive lymphocytes.